Tiny particles, big hope: new combo tackles tough cancers
NCT ID NCT04789486
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injection plus radiation, and researchers will monitor safety and how well the tumors shrink or stop growing. The goal is to find the best dose and see if this combination works better than radiation alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AGuIX gadolinium-based nanoparticles
What this could lead to
If successful, this could offer a more effective way to control central lung tumors and locally advanced pancreatic cancer with fewer side effects.
What could go wrong
This is an early phase 1-2 trial with only 100 participants, so results may not apply broadly. Nanoparticles could cause unexpected toxicity or fail to improve outcomes over standard radiation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact